Cantrell Drug Recalls Glycopyrrolate Injection Due to Sterility Concerns
Cantrell Drug Company is recalling specific lots of Glycopyrrolate injection because the firm cannot assure the sterility of the product.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The FDA classified this recall as Class II. Per the rubric, FDA Class II recalls involving significant injury or property damage reports, or structural defects, are rated as Severe (4). While no specific injuries are reported in the text, the lack of sterility assurance in an IV product is a significant hazard.
Plain-English summary
Cantrell Drug Company is recalling 48,592 syringes of Glycopyrrolate 1 mg/5 mL Injection Solution. The product is distributed nationwide and is intended for intravenous use in hospitals and offices only. The recall involves four specific lots: 9006, 8757, 8954, and 9174.
The recall is being conducted because the firm lacks assurance of the sterility of the selected sterile drug products. The FDA has classified this recall as Class II, indicating that use of, or exposure to, the violative product may cause temporary or medically reversible adverse health consequences.
Healthcare facilities and pharmacies should check their inventory for the affected NDC 52533-028-15 and the specific lot numbers listed above. Patients who have received this medication should contact their healthcare provider for guidance.
The recalled product
- Product
- Glycopyrrolate 1 mg/5 mL (0.2 mg/mL) Injection Solution, 5 mL Single-Dose Syringe, For IV Use, Hospital/Office Use Only, Rx Only, Cantrell Drug Co. 7321 Cantrell Rd. Little Rock, AR 72207, NDC 52533-028-15
- Manufacturer
- Cantrell Drug Company
- Category
- Drug — Sterile Injection
- Hazard
- Affected units
- 48,592
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot: 9006 BUD: 1/20/2017
- Lot: 8757 BUD: 11/30/2016
- Lot: 8954 BUD: 1/6/2017
- Lot: 9174 BUD: 2/20/2017
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 21 recalled by Cantrell Drug Company under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 21 products in this recall →Related recalls
Same manufacturer · Cantrell Drug Company
See all →- SevereCantrell Drug Company Recalls Rocuronium Bromide Injection Due to Sterility Concerns
FDA (Drugs) · 2017-08-16
- SevereCantrell Drug Recalls Succinylcholine Chloride Injection Due to Sterility Concerns
FDA (Drugs) · 2017-08-16
- SevereCantrell Drug Recalls Norepinephrine Bags Due to Sterility Concerns
FDA (Drugs) · 2017-08-16
- SevereCantrell Recalls Neostigmine Methylsulfate Injection Due to Sterility Concerns
FDA (Drugs) · 2017-08-16
- SevereCantrell Drug Recalls Ephedrine Sulfate Syringes Due to Sterility Concerns
FDA (Drugs) · 2017-08-16
Same hazard · sterility failure
See all →- SevereROHTO DIGI-EYE Eye Drops Recalled Over Sterility Assurance Gap
FDA (Drugs) · 2026-07-29
- HighROHTO DRY-AID Eye Drops Recalled Due to Sterility Concerns
FDA (Drugs) · 2026-07-29
- SevereTransvenous Pacing Electrode Tray with Bipolar Balloon Pacing Electrode Recalled
FDA (Devices) · 2026-07-22
- SevereArterial Line Kit with Lidocaine HCL Injection Fails Sterility Testing
FDA (Devices) · 2026-07-22
- SevereOne-Piece Introducer Tray kits recalled for sterility failure
FDA (Devices) · 2026-07-22